AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04835454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: piRNAs, miRNA-194, regucalcin and plasma aminoacids levels
Description: PIWI-interacting RNAs (piRNAs), a class of small nuclear RNA molecules, are associated with the PIWI proteins. MicroRNAs (miRNAs) are conserved small non-coding RNAs (19-22 nucleotide-long) that mediate post-transcriptional regulation of gene expression, affecting mRNA stability and translation by binding complementary sites on target mRNAs. Regucalcin (RGN) is an inhibitory protein of calcium signaling with calcium-binding properties. It plays a multifunctional role in the regulation of cell functions, including maintenance of intracellular calcium homeostasis, inhibitions of protein kinases and protein phosphatases linked to cell signaling process, suppressions of protein production and nuclear DNA and RNA synthesis.Free amino acids, in biological fluids can be a reduced invasive method associated to a high diagnostic potential. It was found that free amino acid profiles vary depending on type of cancer and its stage.
Study NCT03826524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Epinephrine 1mg 1:10000 (10cc) per dose
Study NCT05857254 — intervention group
Intervention type: OTHER
Intervention: Patient with chronic intestinal failure
Description: The negociation component will be assessed during an office visit with the help of forms, by the difference between  ideal  parenteral nutrition prescription proposed by prescriber and the  final  prescription, that the patient ultimately receives at the end of the office visit.~The compliance component will be assessed by a telephone interview, 8 weeks after the office visit.
Study NCT05152303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Loading dose: 0.08mg/kg IV of Remimazolam Tosilate, Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.1mg/kg/h
Study NCT05152303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Loading dose: 0.08mg/kg, Drug: Propofol Injection Maintenance dose: IV remimazolam tosilate, dose range 0-2.0mg/kg/h, increment or decrement of 0.2mg/kg/h IV of Propofol Injection
Study NCT05429047 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tozinameran
Description: Tozinameran during pregnancy
Study NCT05429047 — intervention group
Intervention type: OTHER
Intervention: COVID-19
Description: SARS-CoV-2 infection during pregnancy
Study NCT05429047 — intervention group
Intervention type: OTHER
Intervention: No SARS-CoV-2 exposure
Description: No SARS-CoV-2 exposure during pregnancy
Study NCT03928275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
Study NCT03928275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination therapy Interleukin-2 and Bacillus Calmette Guerin
Description: BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions).
Study NCT04934163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow rate setting of high-flow nasal cannula (initially 60L/min)
Description: The flow rates of HFNC(high-flow nasal cannula) is set as 60L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%.
Study NCT04934163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow rate setting of high-flow nasal cannula (initially 40L/min)
Description: The flow rates of HFNC(high-flow nasal cannula) is set as 40L/min(temperature:34°C).~Initial FiO2 is 100%, which would be titrated down to the minimal level to keep SpO2 ≥ 92% within 30 minutes after extubation.~After that, the flow rate setting is fixed for 24hrs +/- 6 hrs; then, is tapered to 30 L/min and kept for 12 more hours. Afterwards, HFNC would be changed to conventional oxygen therapy to keep SpO2≥ 92%.
Study NCT04788745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride
Description: Oral tablet, twice-daily
Study NCT04948827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBP-9330
Description: SBP-9330 oral capsules
Study NCT04948827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsules
Study NCT06027255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IL-6
Description: Compare IL-6 level , as a marker of inflammation in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae.
Study NCT06027255 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cytokines (IL-17, and IFN-ɣ)
Description: Compare Proinflammatory cells and its secreted cytokines (IL-17, and IFN-ɣ) in all the 3 groups:~* POTS patients~* post-COVID-19 POTS~* gender, age, and BMI-matched controls, with history of COVID-19 infection without sequelae
Study NCT06027255 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Compass 31
Description: Autonomic symptoms assessment questionnaire (COMPASS 31), in post-COVID-19 POTS and compare with POTS patients
Study NCT04829630 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rabies vaccine
Description: * day 0 : questionnaire, blood sampling and vaccine booster (a single session of two intradermal doses of 0.1 mL)~* day 7 : questionnaire and blood sampling
Study NCT06107855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Press Resistance Training Machine
Description: Participants used said unilateral leg press at 60% one-repetition max for either 3 sets x 5 reps, or 5 sets x 5 reps, at either maximal- or controlled-tempo-intent.
Study NCT06357520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet will be administered orally.
Study NCT06357520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole capsule will be administered orally.
Study NCT06777303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcurmin loaded on chitosan nano-particles
Description: the formulation of curcumin and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
Study NCT06777303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid loaded on chitosan nano-particles
Description: the formulation of hyaluronic acid and incorprating it with chitosan nano-particles will increase the absorption rate in the gingival sulcus
Study NCT06777303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling and root planning
Description: the -ve control group in the study
Study NCT06777303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chitosan nano-particles
Description: the +ve control group in the study
Study NCT06783283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial Alternating Current Stimulation (tACS) is a non-invasive electrical stimulation that will be used to stimulate the dorsolateral prefrontal cortex (dlPFC) and temporal cortices and in turn enhance Theta-Gamma Coupling (TGC) and working memory in Mild Cognitive Impairment (MCI). Each participant will receive daily stimulation for 10 days. To deliver the tACS, multiple electrodes embedded in a cap placed on the participant's head. Sham-tACS will follow the same procedure.
Study NCT06783283 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: During sham-tACS, the device will ramp up to the desired intensity over 30 seconds, and then will immediately ramp down, and the stimulation will be shut off, until the end of the session. At the end of the session, the device will again ramp up for 30 seconds and then ramp down. Sham-tACS will also target dlPFC and temporal cortices (similar to active). Each participant will receive daily sham-tACS for 10 days. To deliver the sham-tACS, multiple electrodes will be embedded in a cap placed on the participant's head.
Study NCT06785961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration of traumatic tooth
Description: Revascularization is a new treatment method for immature necrotic , pulp revascularization allows also the stimulation of the apical development and the root maturation of immature teeth ( growth and thickening of dentinal walls ).
Study NCT05465590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB1707
Description: MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.~MB1707, paclitaxel (PTX) conjugated CXC chemokine receptor 4 (CXCR4) peptide antagonist, a peptide-drug conjugate (PDC), for the treatment of cancer. MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway. MB1707 contains a conjugated drug, paclitaxel. By specific binding to CXCR4 overexpressed by the tumor cells, MB1707 has a built-in targeted delivery mechanism.
Study NCT04656184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Description: The patients will receive anakinra, an analogue of the IL-1 receptor antagonist, at a starting dose of 4 mg/kg. If patients are still febrile with 12 hours (H12) of treatment, they will receive a supplementary dose of 2 mg/Kg; otherwise, they will remain at a starting dose of 4 mg/kg. If they are still febrile at H24, they will receive a dose of 8mg/kg; otherwise, they will maintain their dose of 6 mg/kg. Patients with temperature \<38°C at any point between initiation and day 14, but who develop secondary fever due to KD could have further escalation dose of anakinra until a maximum dose of 8mg/Kg. Patients will receive anakinra during 14 days independently of the period of escalation dose if any. After the last escalation dose, if any necessary, the primary criteria will be measured. Patients not responding to anakinra will follow usual standard care and will complete information related to all the study visits
Study NCT01351168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
Study NCT01351168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem first dose
Description: Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
Study NCT01351168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem second dose
Description: Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
Study NCT01351168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
Study NCT04656184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: The patients will receive a standard therapy, IVIG infusion of 2g/kg, and their treatment will follow usual standard care. Patients in the IVIG treatment will complete information related to the study visits.
Study NCT05867966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeduc/self-care/self-hypnosis group
Description: See arm description.
Study NCT05621707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy combined with PD-1 inhibitors
Description: Induction chemotherapy combined with PD-1 inhibitors followed with standard concurrent chemoradiotherapy
Study NCT05084339 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CGM
Description: blinded CGM used at 4 different time points in pregnancy
Study NCT04966975 — intervention group
Intervention type: OTHER
Intervention: neoadjuvant chemotherapy
Description: The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
Study NCT05886907 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lehfilcon A multifocal toric contact lenses
Description: Investigational silicone hydrogel contact lenses
Study NCT05886907 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A multifocal toric contact lenses
Description: Commercially available silicone hydrogel contact lenses
Study NCT05886907 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution
Study NCT05307003 — intervention group
Intervention type: DRUG
Intervention: Trazodone
Description: Medication used to treat ICU delirium
Study NCT05307003 — intervention group
Intervention type: DRUG
Intervention: Quetiapine
Description: Medication used to treat ICU delirium
Study NCT06283433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finger Prick
Description: Blood sample obtained via drop of capillary blood by finger prick onto filter paper
Study NCT06283433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Venipuncture
Description: Blood sample obtained trough venipuncture
Study NCT05168618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05168618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT06179043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrient warning labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* Labels that read high in sugars and high in calories~* A label that reads high in sugars
Study NCT06179043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-only health warning labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay
Study NCT06179043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graphic health warning labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A label that reads Drinking beverages with added sugars contributes to obesity, type 2 diabetes and tooth decay and contains graphics illustrating obesity, type 2 diabetes, and tooth decay~* A label that reads Drinking beverages with added sugars contributes type 2 diabetes and tooth decay and contains graphics illustrating type 2 diabetes and tooth decay
Study NCT06179043 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control labels
Description: In random order, participants in this arm will see an image of fictional sugar-sweetened beverages carrying:~* A neutral bar code label~* A neutral quick response (QR) code label (not scannable)
Study NCT04830553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based couple therapy.
Description: Each couple will receive five treatment sessions, including established methods from client-centered and family-systems psychotherapy as well as Sentire, a technological approach providing immediate sound feedback for physical distance and touch. Duration of the treatment phase: five weeks.
Study NCT05418127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Traditionally-fermented coconut milk kefir
Study NCT05418127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution of Calcium Carbonate and coconut extract
Study NCT05304455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study NCT05304455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole 25Mg Tab
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study NCT05304455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Low Molecular Weight Heparin
Description: From postoperative day 3, Patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin injection for first five days and 2.5 mg oral Apixaban tablets (Bristol-Myers Squibb, Cruiserath, USA) twice daily for 6 months.The Doppler Ultra Sonography screening will be done to assess the occurrence of portal vein thrombus.
Study NCT05759962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQT-1213
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Study NCT05759962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT05761457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryopreserved autologous platelet transfusion
Description: Autologous PLTs were collected and transfused as an individualized treatment approach, when the platelet is less than 20\*10E9/L or severe bleeding occurred.
Study NCT01272505 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: converntional SILC
Study NCT01272505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel Single incision laparoscopic cholecystectomy
Study NCT01272505 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Harmonic scalpel Single incision laparoscopic cholecystectomy
Study NCT02968459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord MSCs
Description: Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
Study NCT02968459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
Study NCT05163938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REThink Therapeutic Game
Description: Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)
Study NCT06102447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netopitam Palonosetron capsules and dexamethasone
Description: On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting.
Study NCT05163938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment As Usual: In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
Study NCT04854057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 4 times per week.
Study NCT04854057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM - Intermittent Room Air - room air mixture
Description: Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 4 times per week.
Study NCT04854057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TESS - Transcutaneous Electrical Spinal Cord Stimulation + Functional Task Practice
Description: Participants will receive transcutaneous electrical stimulation to the cervical spinal cord using the TESCoN device developed by SpineX, Inc. Training will consist of progressive functional task practice for upper extremity motor training. A total of 24 treatment sessions, which will last 45 minutes per session, will be completed in 3 weeks (4 days/week) per crossover arm.